Stockland has labelled Lonergan Edwards valuation of takeover target, Aevum as being "fundamentally flawed". Stockland's objection to the valuation is based on a perceived inconsistency in the discount rate and the growth rate used by Aevum and the rates used by Longeran Edwards to determine their valuation.

For the full story click here.